COMPARTMENTAL PHARMACOKINETIC ANALYSIS OF ORAL AMPRENAVIR WITH SECONDARY PEAKS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 氨丙那韦是一种蛋白酶抑制剂，已被证明有第二个峰，推测是由于肠道-肝脏循环。我们提出了一个模型来描述包含第二峰的氨丙那韦的药代动力学(S)。作为成人艾滋病临床试验小组A5043方案的一部分，共有82名健康的人类免疫缺陷病毒(HIV)血清阴性受试者接受了单剂量600毫克的氨丙那韦治疗。连续采集24小时的血样。用Adapt II软件分析氨丙那韦，并符合房室模型，所有相关参数均以生物利用度为条件。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Amprenavir is a protease inhibitor that has been shown to have secondary peaks postulated to be due to enterohepatic recycling. We propose a model to describe the pharmacokinetics of amprenavir which accommodates the secondary peak(s). A total of 82 healthy human immunodeficiency virus (HIV)-seronegative subjects were administered a single 600-mg dose of amprenavir as part of adult AIDS Clinical Trials Group protocol A5043. Serial blood samples were obtained over 24 h. Samples were analyzed for amprenavir and fit to a compartmental model using ADAPT II software, with all relevant parameters conditional with respect to bioavailability.